Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 08, 2024

SELL
$16.07 - $31.84 $14,463 - $28,656
-900 Reduced 65.93%
465 $13,000
Q1 2024

May 15, 2024

BUY
$17.13 - $26.91 $10,021 - $15,742
585 Added 75.0%
1,365 $28,000
Q4 2023

Feb 12, 2024

BUY
$21.58 - $29.5 $1,079 - $1,475
50 Added 6.85%
780 $21,000
Q3 2023

Nov 13, 2023

BUY
$25.8 - $39.97 $5,160 - $7,994
200 Added 37.74%
730 $21,000
Q1 2023

May 15, 2023

BUY
$22.92 - $33.76 $114 - $168
5 Added 0.95%
530 $12,000
Q4 2022

Feb 15, 2023

SELL
$25.44 - $59.78 $915 - $2,152
-36 Reduced 6.42%
525 $14,000
Q3 2022

Nov 10, 2022

SELL
$43.66 - $61.0 $742 - $1,037
-17 Reduced 2.94%
561 $30,000
Q2 2022

Aug 04, 2022

SELL
$28.82 - $77.35 $576 - $1,547
-20 Reduced 3.34%
578 $23,000
Q1 2022

May 02, 2022

SELL
$48.25 - $100.49 $6,127 - $12,762
-127 Reduced 17.52%
598 $40,000
Q3 2021

Nov 12, 2021

SELL
$98.77 - $132.17 $10,272 - $13,745
-104 Reduced 12.55%
725 $91,000
Q2 2021

Aug 13, 2021

BUY
$109.77 - $165.68 $58,726 - $88,638
535 Added 181.97%
829 $103,000
Q1 2021

May 14, 2021

BUY
$127.04 - $179.1 $31,124 - $43,879
245 Added 500.0%
294 $44,000
Q4 2020

Feb 11, 2021

BUY
$99.96 - $135.93 $899 - $1,223
9 Added 22.5%
49 $6,000
Q3 2020

Oct 30, 2020

SELL
$80.32 - $111.8 $8,031 - $11,180
-100 Reduced 71.43%
40 $4,000
Q1 2020

Apr 29, 2020

SELL
$59.04 - $88.81 $5,904 - $8,881
-100 Reduced 41.67%
140 $9,000
Q4 2019

Jan 17, 2020

SELL
$59.49 - $82.78 $18,560 - $25,827
-312 Reduced 56.52%
240 $18,000
Q3 2019

Oct 30, 2019

SELL
$62.59 - $110.3 $25,787 - $45,443
-412 Reduced 42.74%
552 $35,000
Q2 2019

Jul 25, 2019

BUY
$63.94 - $91.11 $61,638 - $87,830
964 New
964 $83,000

Others Institutions Holding GH

About Guardant Health, Inc.


  • Ticker GH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 102,220,000
  • Market Cap $3.59B
  • Description
  • Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a cl...
More about GH
Track This Portfolio

Track Steward Partners Investment Advisory, LLC Portfolio

Follow Steward Partners Investment Advisory, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Steward Partners Investment Advisory, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Steward Partners Investment Advisory, LLC with notifications on news.